BiotechTube

Pasireotide LAR 60 mg + Pegvisomant

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Acromegaly

Conditions

Acromegaly

Trial Timeline

Aug 1, 2015 → Jun 1, 2017

NCT ID
NCT02668172

About Pasireotide LAR 60 mg + Pegvisomant

Pasireotide LAR 60 mg + Pegvisomant is a approved stage product being developed by Novartis for Acromegaly. The current trial status is unknown. This product is registered under clinical trial identifier NCT02668172. Target conditions include Acromegaly.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02668172ApprovedUNKNOWN

Competing Products

20 competing products in Acromegaly

See all competitors
ProductCompanyStageHype Score
AlesseNovartisPhase 2
52
ONO-5788 + ONO-5788 Placebo + OctreotideOno PharmaceuticalPhase 1
33
ONO-5788 + [14C]-ONO-5788Ono PharmaceuticalPhase 1
33
Pasireotide LARNovartisPhase 3
77
Octreotide acetate 30 mg suspensionNovartisPhase 3
77
Pasireotide long acting release formulationNovartisPre-clinical
23
Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
85
Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
85
Sandostatin LARNovartisApproved
85
Pasireotide + OctreotideNovartisPhase 3
77
Sandostatin (Octreotide Acetate)NovartisApproved
85
Octreotide acetateNovartisApproved
85
octreotide FluidCrystal® injection depotNovartisPhase 2
52
Octreotide LARNovartisPhase 3
77
Octreotide LARNovartisPhase 3
77
PasireotideNovartisPhase 2
52
OctreotideNovartisApproved
85
Octreotide LAR 30 MG InjectionNovartisApproved
85
Pasireotide LARNovartisPhase 2
52
Pasireotide (SOM230), Octreotide (Sandostatin)NovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85